ImmunoGen, Inc. (NASDAQ:IMGN) shares gained 8% to $14.92
after partner Roche Holding AG said its experimental breast cancer drug
significantly extended the lives of patients when compared with standard
therapy. The treatment, dubbed T-DM1, for people with HER2-positive metastatic
breast cancer, combines Basel, Switzerland-based Roche’s Herceptin with
ImmunoGen’s technology that helps the treatment carry chemotherapy directly
into malignant cells while bypassing healthy ones.
Can
IMGN Continue To Move Higher? Find Out Here
Orion Energy Systems, Inc. (NYSEAMEX:OESX), in
August 2012, received a subpoena issued by the staff of the Securities and
Exchange Commission requesting certain documents and information generally
related to the Company’s financial reporting of its sales of solar photovoltaic
systems, among other matters.
M&T Bank Corporation (NYSE:MTB) stock increased
1.32% to $87 in the pre-market hour after Hudson City Bancorp and M&T Bank
Corporation announced they have entered into a definitive agreement under which
Hudson City will merge into a subsidiary of M&T. Each Hudson City share
will receive consideration valued at 0.08403 of an M&T share in the form of
either M&T stock or cash, based upon the election of each Hudson City
shareholder.
Additionally, the company announced that it has
declared a quarterly cash dividend of $.70 per share on its common stock. The
dividend will be payable September 28, 2012 to shareholders of record at the
close of business on September 4, 2012.
Vringo, Inc. (NYSEAMEX:VRNG) stock declined 6% to
$3.34 in the opening session. There are less than two months left until Vringo
and Google go head-to-head in court. Vringo has emerged as a $200 million
company largely due to its lawsuit threats against Google and other search
engines like AOL.
Can
VRNG Bounce Back Now? Find Out Here
No comments:
Post a Comment